Skip to content
Screener

Ocular Therapeutix OCUL Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$14.5MMiss by $1.6M
EPS-$0.37Beat by $0.02
Revenue estimate$16.1M
EPS estimate-$0.39

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$14.3M
EPS estimate-$0.36

Financials

Q3 2025

Income statement

See full
Revenue$14.5M-5.7%
Gross profit$12.8M-7.9%
Operating income-$68.7M-49.3%
Net income-$69.4M-90.2%
EPS (diluted)-$0.38-72.7%

Balance sheet

See full
Cash & equivalents$344.8M-19.3%
Total debt$77.0M+2.5%
Total equity$258.2M-26.6%
Total assets$410.9M-16.2%

Cash flow

See full
Operating cash flow-$50.7M-38.7%
CapEx$6.0M+6,634%
Free cash flow-$56.7M-54.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.03B+41.0%
Enterprise value$1.77B+62.0%
P/S36.5×+13.0×

Profitability

See full
Gross margin88.9%-1.7pp
Operating margin-449.7%+9,735pp
Net margin-447.6%+611pp
FCF margin-357.5%+1,907pp

Returns & leverage

See full
Return on equity-81.8%-11.0pp
Debt / equity0.3×+0.1×
Current ratio7.9×-5.2×

Segments

By segment

See full
Single Reportable$14.5M-5.7%

FAQ

When did Ocular Therapeutix report Q3 2025 earnings?
Ocular Therapeutix (OCUL) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Ocular Therapeutix's Q3 2025 revenue and EPS?
Ocular Therapeutix reported revenue of $14.5M and eps of $-0.37 for Q3 2025.
Did Ocular Therapeutix beat estimates in Q3 2025?
Revenue missed the consensus estimate of $16.1M by $1.6M. EPS beat the consensus estimate of $-0.39 by $0.02.
How did Ocular Therapeutix's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 5.7% from $15.4M a year earlier and eps declined 42.3% from $-0.26.
Where can I find Ocular Therapeutix's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-105914) and the 10-Q periodic report (0001104659-25-105919) directly on SEC EDGAR. The filing index links above go to sec.gov.